FDA Grants Moxetumomab Pasudotox Priority Review for Hairy Cell Leukemia

/1 Comment/in , /by

The FDA has granted a priority review to moxetumomab pasudotox for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy.

Read full article (External website)

You might also like
Durvalumab Success Signifies New Era in Stage III NSCLC Durvalumab Success Signifies New Era in Stage III NSCLC
Social Network Index Developed to Assess the Support Resources of Adolescent and Young Adult Cancer Survivors
Expert Sheds Light on Recent Advances in mCRC
Expert Discusses Bone-Targeting Agents in Prostate Cancer
Managing Eating Challenges After Head and Neck Cancer Treatment
Larotrectinib Exceeds 90% Response Rate in TRK+ Pediatric Cancers
EMA to Review Olaparib in BRCA-mutated, HER2-negative Breast Cancer
NCT02578680 Keynote189 pembrolizumab chemotherapy nsclc NEJM Leena Gandhi Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Nonsquamous NSCLC
1 reply

Trackbacks & Pingbacks

  1. FDA Grants Moxetumomab Pasudotox Priority Review for Hairy Cell Leukemia - MediNews Asia says:
    April 17, 2018 at 10:48 pm

    […] FDA Grants Moxetumomab Pasudotox Priority Review for Hairy Cell Leukemia […]

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply